INTERNATIONAL PATENT: ASTRAZENECA AB FILES APPLICATION FOR "DOSE-DEPENDENT ADMINISTRATION OF INHIBITOR OF PNPLA3 EXPRESSION"

GENEVA, Oct. 13 -- ASTRAZENECA AB (SE-151-85Sodertalje) filed a patent application (PCT/IB2025/053464) for "DOSE-DEPENDENT ADMINISTRATION OF INHIBITOR OF PNPLA3 EXPRESSION" on Apr 02, 2025. With publication no. WO/2025/210536, the details related to the patent application was published on Oct 09, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): NIAZI, Mohammad (AstraZeneca ABSE-151 85Sodertalje), ANTONSSON, Madeleine (AstraZeneca ABSE-151 85Sodertalje), BERGENHOLM, Linnea (AstraZeneca ABSE-151 85Sodertalje), CARLSSON, Bjorn (AstraZeneca ABSE-151 85Sodertalje), FJELLSTROM, Ola (AstraZeneca ABS...